Exploring the Optimal Dose of Esketamine for Preventing Postpartum Depression

Effects of Different Doses of Esketamine on the Prevention of Postpartum Depression and Postoperative Pain in Parturients Undergoing Cesarean Section: A Dose-Finding Study Based on U-BOIN Design

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600128246

Enrollment

Unknown

Registered

2026-07-16

Start date

2026-08-31

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum depression

Interventions

Dose group:According to the U-BOIN design process, different doses of Esketamine were given.

Eligibility

Sex/Gender

Female

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 20 years old; 2. Full-term singleton pregnant women scheduled for elective cesarean section under neuraxial anesthesia; 3. Fully understand this study, participate voluntarily, and sign the informed consent form personally;

Exclusion criteria

Exclusion criteria: 1. Previous personal or family history of psychiatric disorders, or concurrent use of other antidepressants; 2. Patients with communication disorders; 3. Subjects with contraindications to esketamine, including hyperthyroidism, gestational hypertension or preeclampsia, elevated intracranial pressure, elevated intraocular pressure, elevated intragastric pressure, etc.; 4. Combined severe cardiac, pulmonary, hepatic or renal dysfunction; 5. Allergy to local anesthetics;

Design outcomes

Primary

Measure	Time frame
occurrence of adverse events;Incidence of postpartum depression;	—

Countries

China

Contacts

Public ContactWei Ke

The First Affiliated Hospital of Chongqing Medical University

962881848@qq.com+86 23 89011876

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026